

cell attracting chemokine), mMIP-1 γ (murine macrophage inflammatory protein 1 γ), or vMIPII (viral macrophage inflammatory protein II) in a cell or tissue in the mammal.

34. (Amended) The method of claim 33, wherein the agent inhibits the binding of CCX CKR to ELC, SLC, TECK, BLC, CTACK, mMIP-1 γ or vMIPII.

B² 35. (Amended) The method of claim 33, wherein the CCX CKR-mediated condition is selected from the group consisting of inflammation, an allergic disease, an autoimmune disease, graft rejection, cancer, an infectious disease or an immunosuppressive disease.

36. (Amended) The method of claim 35, wherein the CCX CKR-mediated condition is inflammation.

Please add the following new claims:

37. (New) The method of claim 33, wherein the agent promotes the binding of CCX CKR to ELC, SLC TECK, BLC, CTACK, mMIP-1 γ , or vMIPII.

38. (New) The method of claim 35, wherein the CCX CKR-mediated condition is an allergic disease.

39. (New) The method of claim 35, wherein the CCX CKR-mediated condition is an autoimmune disease.

B³ 40. (New) The method of claim 35, wherein the CCX CKR-mediated condition is graft rejection.

41. (New) The method of claim 35, wherein the CCX CKR-mediated condition is cancer.

42. (New) The method of claim 35, wherein the CCX CKR-mediated condition is an infectious disease.

43. (New) The method of claim 35, wherein the CCX CKR-mediated condition is an immunosuppressive disease.

44. (New) The method of claim 33, wherein the mammal is a human.

45. (New) The method of claim 33, wherein the mammal is a non-human primate.

46. (New) The method of claim 33, wherein the agent is an antibody.

47. (New) The method of claim 34, wherein
the mammal is a human; and
the CCX CKR-mediated condition is selected from the group consisting of
inflammation, an allergic disease, an autoimmune disease, graft rejection, cancer, an
infectious disease or an immunosuppressive disease.

48. (New) The method of claim 37, wherein
the mammal is a human; and
the CCX CKR-mediated condition is selected from the group consisting of
inflammation, an allergic disease, an autoimmune disease, graft rejection, cancer, an
infectious disease or an immunosuppressive disease. --

RESPONSE TO RESTRICTION REQUIREMENT

In response to the restriction requirement, Applicants elect, without traverse, Group IX, including original claims 33-36 and new claims 37-48.

REMARKS

Claims 1-36 are pending, with claims 1- 32 canceled without prejudice or disclaimer and new claims 37 to 51 introduced upon entry of this amendment. The new and amended claims find support throughout the specification including, for example, the following sections:

Claim 33: Original claims 32 and 33; page 34, line 26-29; page 39, line 1 to
page 46, line 23; and page 51, line 15 to page 53, line 6.